Y-Biologics (XKRX:338840) Total Liabilities : ₩4,446 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Total Liabilities?

Y-Biologics's Total Liabilities for the quarter that ended in Mar. 2024 was ₩4,446 Mil.

Y-Biologics's quarterly Total Liabilities declined from Sep. 2023 (₩12,192.45 Mil) to Dec. 2023 (₩6,885.55 Mil) and declined from Dec. 2023 (₩6,885.55 Mil) to Mar. 2024 (₩4,445.89 Mil).

Y-Biologics's annual Total Liabilities declined from Dec. 2020 (₩19,205.93 Mil) to Dec. 2021 (₩9,803.24 Mil) but then increased from Dec. 2021 (₩9,803.24 Mil) to Dec. 2022 (₩17,029.48 Mil).

Y-Biologics Total Liabilities Historical Data

The historical data trend for Y-Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Total Liabilities Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

28,384.17

30,108.07

19,205.93

9,803.24

17,029.48

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial				13,624.00	13,579.92	12,192.45	6,885.55	4,445.89

Y-Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Y-Biologics's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16195.42	+	(188.099	+	645.963
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	17,029

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	29322.649	-	12293.167
	=	17,029

Y-Biologics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3066.184	+	(689.604	+	690.097
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4,446

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	26817.592	-	22371.706
	=	4,446

Y-Biologics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-Biologics (XKRX:338840) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR

Website

https://www.ybiologics.com

Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines